Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
112.06(c) 114.03(c) 119.2(c) 121.91(c) 121.89(c) Last
1 271 295 1 565 349 2 027 098 1 330 487 1 597 205 Volume
+4.90% +1.76% +4.53% +2.27% -0.02% Change
More quotes
Financials (USD)
Sales 2021 1 721 M - -
Net income 2021 -461 M - -
Net Debt 2021 1 201 M - -
P/E ratio 2021 -41,4x
Yield 2021 -
Sales 2022 2 134 M - -
Net income 2022 -434 M - -
Net Debt 2022 1 474 M - -
P/E ratio 2022 -48,8x
Yield 2022 -
Capitalization 20 910 M 20 910 M -
EV / Sales 2021 12,8x
EV / Sales 2022 10,5x
Nbr of Employees 4 900
Free-Float 99,0%
More Financials
Company
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to... 
Sector
Biotechnology & Medical Research
Calendar
06/16 | 10:05amPresentation
More about the company
Ratings of Exact Sciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about EXACT SCIENCES CORPORATION
06/04EXACT SCIENCESá : Insider Sales at Exact Sciences (EXAS) are Significant and Ext..
MT
06/03INSIDER TRENDS : Selling By Insiders Lingers at Exact Sciences
MT
06/03INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Exact Sciences
MT
06/03EXACT SCIENCESá : Goldman Sachs Starts Exact Sciences at Buy With $160 Price Tar..
MT
05/26EXACT SCIENCESá : New Analysis Reinforces Cost-Effectiveness of the Oncotype DX ..
PU
05/26EXACT SCIENCESá : Strengthens Evidence Supporting Cologuard« and Oncotype DX« Te..
PU
05/25EXACT SCIENCESá : Wells Fargo Initiates Exact Sciences at Equal-Weight With $115..
MT
05/24EXACT SCIENCESá : to participate in June investor conferences
PR
05/21EXACT SCIENCESá : Presents Modeling Data Showing Cologuard 'Superior' for Colore..
MT
05/20EXACT SCIENCESá : New Analysis Reinforces Cost-Effectiveness of the Oncotype DX ..
PU
05/19EXACT SCIENCESá : Applauds Final Task Force Recommendation That Lowers Starting ..
PU
05/18EXACT SCIENCESá : New Analysis Reinforces Cost-Effectiveness of the Oncotype DX ..
PU
05/12EXACT SCIENCESá : Truist Securities Adjusts Exact Sciences' Price Target to $168..
MT
05/05EXACT SCIENCESá : SVB Leerink Adjusts Exact Sciences PT to $170 From $180, Maint..
MT
05/05EXACT SCIENCESá : UBS Adjusts Exact Sciences' Price Target to $139 From $154; Ne..
MT
More news
News in other languages on EXACT SCIENCES CORPORATION
2019STOCK MARKET PARIS : Attention, semaine très chargée !
2019EN DIRECT DES MARCHESá: Sanofi, Airbus, Air France KLM, CNP, Refinitiv, Mylan..
2014Wall Street en légère baisse, l'Ukraine toujours en ligne de mire
2014Les valeurs à suivre sur les marchés américains
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 153,33 $
Last Close Price 121,89 $
Spread / Highest target 51,8%
Spread / Average Target 25,8%
Spread / Lowest Target -37,6%
EPS Revisions
Managers and Directors
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION-8.00%20 910
GUARDANT HEALTH, INC.-6.16%12 230
BGI GENOMICS CO., LTD.-7.00%7 659
INVITAE CORPORATION-25.33%6 239
ADAPTIVE BIOTECHNOLOGIES CORPORATION-34.45%5 438
CAREDX, INC25.95%4 750